Masitinib found superior to standard GIST treatment: AB Science reports
Masitinib is an investigational orally administered tyrosine kinase inhibitor that targets mast cells, essential for immunity. In the study, 44 patients with inoperable, locally advanced or metastatic GIST
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.